FRTB: Basel guidance on backtesting frustrates dealers

Dealers blast “illogical” carve-outs for backtesting exceptions

Business people struggling with figures
Struggling with the figures: “This doesn’t make sense," says one market risk specialist

Dealers have been left frustrated by the Basel Committee’s response to questions on model backtesting under the revised market risk framework. One dealer complains the provisions – which seek to clarify the circumstances in which trading desks can ignore backtesting breaches that are attributable to illiquid risk factors – “make no sense”, while others interpret them as likely to load unjustified capital charges on to banks.

The committee’s FAQ document, published on January 26, addressing

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options


Want to know what’s included in our free membership? Click here

This address will be used to create your account

The new rules of market risk management

Amid 2020’s Covid-19-related market turmoil – with volatility and value-at-risk (VAR) measures soaring – some of the world’s largest investment banks took advantage of the extraordinary conditions to notch up record trading revenues. In a recent…

ETF strategies to manage market volatility

Money managers and institutional investors are re-evaluating investment strategies in the face of rapidly shifting market conditions. Consequently, selective genres of exchange-traded funds (ETFs) are seeing robust growth in assets. Hong Kong Exchanges…

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here